Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.
The Indian drugmaker highlighted resilience in its domestic formulations business. This segment continued to deliver solid performance amid broader market conditions.
Corporate India posted robust revenue increases during the March 2026 quarter. However, rising input costs and a weaker rupee pressured operating margins across many companies.
Ti AI ṣe iroyin
India's listed brokers and exchanges posted strong results for the March quarter. Growth came from higher margin trading and increased market activity.
Gokaldas Exports achieved strong sequential growth in both revenue and profit for the March quarter. The company posted a 9% rise in revenue despite ongoing global trade disruptions and US tariff pressures.
Ti AI ṣe iroyin
Tata Consumer Products posted a consolidated net profit of Rs 419 crore for the fourth quarter, marking a 21% increase from the previous year. Revenue from operations grew 18% year-over-year to Rs 5,434 crore.